Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences operating margin
Operating margin is operating income as a percentage of revenue.
Gilead Sciences's operating margin for the twelve months ending Sep 30, 2026 was -7.6%. For fiscal 2025 it was 34.0%, against 5.8% the year before. The highest annual figure on record is 68.0% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.0% | +28.3 |
| FY2024 | Dec 31, 2024 | 5.8% | −22.3 |
| FY2023 | Dec 31, 2023 | 28.0% | +1.2 |
| FY2022 | Dec 31, 2022 | 26.9% | −9.5 |
| FY2021 | Dec 31, 2021 | 36.3% | +19.8 |
| FY2020 | Dec 31, 2020 | 16.5% | −2.6 |
| FY2019 | Dec 31, 2019 | 19.1% | −18.0 |
| FY2018 | Dec 31, 2018 | 37.1% | −17.0 |
| FY2017 | Dec 31, 2017 | 54.1% | −3.9 |
| FY2016 | Dec 31, 2016 | 58.0% | −10.0 |
| FY2015 | Dec 31, 2015 | 68.0% | +6.7 |
| FY2014 | Dec 31, 2014 | 61.3% | +20.9 |
| FY2013 | Dec 31, 2013 | 40.4% | −0.9 |
| FY2012 | Dec 31, 2012 | 41.3% | −3.9 |
| FY2011 | Dec 31, 2011 | 45.2% | −4.6 |
| FY2010 | Dec 31, 2010 | 49.8% | −0.5 |
| FY2009 | Dec 31, 2009 | 50.3% | +0.1 |
| FY2008 | Dec 31, 2008 | 50.2% | −1.0 |
| FY2007 | Dec 31, 2007 | 51.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 41.7% | −1.1 |
| Q2 FY2026 | Jun 30, 2026 | -133.2% | −168.1 |
| Q1 FY2026 | Mar 31, 2026 | 37.2% | +3.6 |
| Q4 FY2025 | Dec 31, 2025 | 25.0% | −7.4 |
| Q3 FY2025 | Sep 30, 2025 | 42.8% | +31.1 |
| Q2 FY2025 | Jun 30, 2025 | 34.9% | −3.1 |
| Q1 FY2025 | Mar 31, 2025 | 33.6% | +98.2 |
| Q4 FY2024 | Dec 31, 2024 | 32.4% | +9.7 |
| Q3 FY2024 | Sep 30, 2024 | 11.8% | −25.4 |
| Q2 FY2024 | Jun 30, 2024 | 38.0% | +12.8 |
| Q1 FY2024 | Mar 31, 2024 | -64.6% | −91.5 |
| Q4 FY2023 | Dec 31, 2023 | 22.7% | −8.0 |
| Q3 FY2023 | Sep 30, 2023 | 37.2% | −3.1 |
| Q2 FY2023 | Jun 30, 2023 | 25.2% | −7.2 |
| Q1 FY2023 | Mar 31, 2023 | 26.8% | +23.9 |
| Q4 FY2022 | Dec 31, 2022 | 30.7% | +17.7 |
| Q3 FY2022 | Sep 30, 2022 | 40.3% | −11.5 |
| Q2 FY2022 | Jun 30, 2022 | 32.4% | −3.7 |
| Q1 FY2022 | Mar 31, 2022 | 3.0% | −42.0 |
| Q4 FY2021 | Dec 31, 2021 | 13.0% | −22.7 |
| Q3 FY2021 | Sep 30, 2021 | 51.8% | +21.3 |
| Q2 FY2021 | Jun 30, 2021 | 36.1% | +94.1 |
| Q1 FY2021 | Mar 31, 2021 | 45.0% | +1.7 |
| Q4 FY2020 | Dec 31, 2020 | 35.7% | +17.1 |
| Q3 FY2020 | Sep 30, 2020 | 30.4% | +56.7 |
| Q2 FY2020 | Jun 30, 2020 | -58.0% | −100.7 |
| Q1 FY2020 | Mar 31, 2020 | 43.3% | +0.9 |
| Q4 FY2019 | Dec 31, 2019 | 18.6% | −1.1 |
| Q3 FY2019 | Sep 30, 2019 | -26.3% | −73.2 |
| Q2 FY2019 | Jun 30, 2019 | 42.7% | +2.4 |
| Q1 FY2019 | Mar 31, 2019 | 42.4% | +0.0 |
| Q4 FY2018 | Dec 31, 2018 | 19.7% | −18.8 |
| Q3 FY2018 | Sep 30, 2018 | 46.9% | −11.7 |
| Q2 FY2018 | Jun 30, 2018 | 40.4% | −19.2 |
| Q1 FY2018 | Mar 31, 2018 | 42.3% | −15.6 |
| Q4 FY2017 | Dec 31, 2017 | 38.5% | −16.7 |
| Q3 FY2017 | Sep 30, 2017 | 58.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 59.6% | – |
| Q1 FY2017 | Mar 31, 2017 | 57.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 55.3% | – |
See a number that looks wrong?